Kamada's (and GTCB's) competitor (I think I've mentioned them somewhere else like here <a href='read_msg.asp?message_id=25991026'>#msg-25991026</a>) Arriva Pharmaceuticals moves forward to Phase IIb development of lead inhaled protein rAAT replacement therapy for hereditary emphysema. <a href="http://www.earthtimes.org/articles/show/arriva-pharmaceuticals-moves-forward-to-phase-2b-development-of-lead,296031.shtml" target="_blank">http://www.earthtimes.org/articles/show/arriva-pharmaceuticals-moves-forward-to-phase-2b-development-of-lead,296031.shtml</a>
Market Data 
Markets 
AI
